Back to Studies
P1085 / Human Papilloma Virus (HPV) Type-Specific Antibody
Duration of Human Papilloma Virus (HPV) Type-Specific Antibody After Administration of Quadrivalent HPV Vaccine to HIV-infected Children
Primary Protocol Team Members
Summary
P1085 is a follow up study of participants enrolled in P1047 to determine the long term immunogenicity of quadrivalent HPV (QHPV) vaccine in HIV-1 infected children. The study is designed to determine the HPV-type specific antibody levels at 2, 3.5, and 5 years after completion of the QHPV vaccine schedule and compare these to published levels of QHPV-induced antibody levels of HIV uninfected children.
Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...